Lunai Bioworks Inc. (LNAI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lunai Bioworks Inc. (LNAI) has a cash flow conversion efficiency ratio of 0.107x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.03 Million) by net assets ($-9.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Lunai Bioworks Inc. (LNAI) market capitalisation for the company's overall valuation and market capitalisation.
Lunai Bioworks Inc. - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Lunai Bioworks Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Lunai Bioworks Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lunai Bioworks Inc. ranked by their cash flow conversion efficiency. Explore Lunai Bioworks Inc. (LNAI) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Buru Energy Ltd
AU:BRU
|
-0.286x |
|
Nvni Group Limited Ordinary Shares
NASDAQ:NVNI
|
0.049x |
|
Jackpot Digital Inc
V:JJ
|
0.170x |
|
Kumulus Vape SA
PA:ALVAP
|
-0.027x |
|
Effnetplattformen Holding AB
ST:EFFH
|
-0.125x |
|
Intensity Therapeutics, Inc. Common stock
NASDAQ:INTS
|
-0.183x |
|
Euroland Corporate SA
PA:MLERO
|
N/A |
|
Hiap Huat Holdings Bhd
KLSE:0160
|
0.130x |
Annual Cash Flow Conversion Efficiency for Lunai Bioworks Inc. (2021–2025)
The table below shows the annual cash flow conversion efficiency of Lunai Bioworks Inc. from 2021 to 2025. View LNAI stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $-21.35 Million | $-7.87 Million | 0.369x | +543.68% |
| 2024-06-30 | $131.98 Million | $-10.97 Million | -0.083x | +67.17% |
| 2023-06-30 | $46.50 Million | $-11.77 Million | -0.253x | -16.88% |
| 2022-06-30 | $72.62 Million | $-15.73 Million | -0.217x | -83.59% |
| 2021-06-30 | $174.66 Million | $-20.61 Million | -0.118x | -- |
About Lunai Bioworks Inc.
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; a… Read more